Xavier Montalban, EAN 2020 – Long-term Phase II Outcomes of First Oral BTK Inhibitor in MS

Xavier Montalban (St Michael’s Hospital, University of Toronto, Toronto, Canada and Vall d’Hebron University Hospital, Barcelona, Spain) shares his expert insights on the rationale for the use of evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in the treatment of patients with relapsing multiple sclerosis (MS), as well as an overview of key efficacy and safety findings from a recent phase II open-label extension study, which were presented as a late-breaking presentation (ClinicalTrials.gov Identifier: NCT02975349).

Questions
1. What is the rationale for the use of evobrutinib in patients with relapsing multiple sclerosis (MS) and what advantages does it confer compared to current therapeutic options? (0:05)
2. Could you give us an overview of the recent phase II study, its patient population and its long-term efficacy and safety findings? (0:50)
3. What, if any, were the limitations of this study? (1:52)
4. Which patients are most likely to respond to evobrutinib? (2:28)
5. What will be the next steps in the clinical development of evobrutinib for MS? (3:05)

Speaker disclosure: Xavier Montalban has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, Genzyme, Immunic, Medday, Merck, Mylan, Nervgen, Novartis, Roche, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.

Support: Interview and filming supported by Touch Medical Media.

Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.